BR112023023726A2 - Compostos heterocíclicos substituídos - Google Patents
Compostos heterocíclicos substituídosInfo
- Publication number
- BR112023023726A2 BR112023023726A2 BR112023023726A BR112023023726A BR112023023726A2 BR 112023023726 A2 BR112023023726 A2 BR 112023023726A2 BR 112023023726 A BR112023023726 A BR 112023023726A BR 112023023726 A BR112023023726 A BR 112023023726A BR 112023023726 A2 BR112023023726 A2 BR 112023023726A2
- Authority
- BR
- Brazil
- Prior art keywords
- substituted heterocyclic
- heterocyclic compounds
- compounds
- useful
- tyk
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188498P | 2021-05-14 | 2021-05-14 | |
| US202263318508P | 2022-03-10 | 2022-03-10 | |
| PCT/US2022/029117 WO2022241174A1 (en) | 2021-05-14 | 2022-05-13 | Substituted heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023023726A2 true BR112023023726A2 (pt) | 2024-01-30 |
Family
ID=81927791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023023726A BR112023023726A2 (pt) | 2021-05-14 | 2022-05-13 | Compostos heterocíclicos substituídos |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11884650B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4337648B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7818623B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240008338A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022272725A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023023726A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3218579A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3059456T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308422A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023013351A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202311248A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022241174A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN122520625A (zh) | 2020-12-22 | 2026-08-07 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物及其制备方法和用途 |
| US12668594B2 (en) | 2020-12-23 | 2026-06-30 | Sudo Biosciences Limited | TYK2 inhibitors and uses thereof |
| IL305119A (en) | 2021-02-19 | 2023-10-01 | Sudo Biosciences Ltd | Tyk2 inhibitors and uses thereof |
| TW202302583A (zh) | 2021-02-19 | 2023-01-16 | 英商蘇多生物科學有限公司 | Tyk2抑制劑及其用途 |
| KR20230159421A (ko) | 2021-02-19 | 2023-11-21 | 수도 바이오사이언시즈 리미티드 | Tyk2 억제제 및 이의 용도 |
| EP4337650A1 (en) * | 2021-05-14 | 2024-03-20 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| US20240317718A1 (en) * | 2021-05-14 | 2024-09-26 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| KR20240007242A (ko) * | 2021-05-14 | 2024-01-16 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 헤테로시클릭 화합물 |
| CN117263913A (zh) | 2022-06-20 | 2023-12-22 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物、固体形式、制备方法及其用途 |
| CN118812511A (zh) * | 2023-04-21 | 2024-10-22 | 浙江文达医药科技有限公司 | 作为tyk2抑制剂的杂环化合物及合成和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2922841B8 (en) * | 2012-11-08 | 2017-08-02 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| RS66346B1 (sr) | 2018-10-22 | 2025-01-31 | Alumis Inc | Inhibitori tyk2 i njihova upotreba |
| KR102858043B1 (ko) * | 2018-10-30 | 2025-09-10 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물 |
| US20230295119A1 (en) | 2020-04-14 | 2023-09-21 | Gossamer Bio Services, Inc. | Substituted pyridines for the treatment of inflammatory diseases |
| PE20250262A1 (es) | 2021-05-14 | 2025-01-29 | Bristol Myers Squibb Co | Compuestos heterociclicos sustituidos |
| EP4337650A1 (en) | 2021-05-14 | 2024-03-20 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| US20240317718A1 (en) | 2021-05-14 | 2024-09-26 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| KR20240007242A (ko) | 2021-05-14 | 2024-01-16 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 헤테로시클릭 화합물 |
-
2022
- 2022-05-13 KR KR1020237042732A patent/KR20240008338A/ko active Pending
- 2022-05-13 CA CA3218579A patent/CA3218579A1/en active Pending
- 2022-05-13 TW TW111118147A patent/TW202311248A/zh unknown
- 2022-05-13 JP JP2023570166A patent/JP7818623B2/ja active Active
- 2022-05-13 US US17/743,615 patent/US11884650B2/en active Active
- 2022-05-13 BR BR112023023726A patent/BR112023023726A2/pt not_active Application Discontinuation
- 2022-05-13 MX MX2023013351A patent/MX2023013351A/es unknown
- 2022-05-13 IL IL308422A patent/IL308422A/en unknown
- 2022-05-13 ES ES22727681T patent/ES3059456T3/es active Active
- 2022-05-13 EP EP22727681.3A patent/EP4337648B1/en active Active
- 2022-05-13 WO PCT/US2022/029117 patent/WO2022241174A1/en not_active Ceased
- 2022-05-13 AU AU2022272725A patent/AU2022272725A1/en not_active Abandoned
-
2023
- 2023-12-14 US US18/539,519 patent/US20240124421A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240124421A1 (en) | 2024-04-18 |
| EP4337648A1 (en) | 2024-03-20 |
| US20220388987A1 (en) | 2022-12-08 |
| US11884650B2 (en) | 2024-01-30 |
| JP2024518555A (ja) | 2024-05-01 |
| TW202311248A (zh) | 2023-03-16 |
| JP7818623B2 (ja) | 2026-02-20 |
| CA3218579A1 (en) | 2022-11-17 |
| MX2023013351A (es) | 2023-11-27 |
| IL308422A (en) | 2024-01-01 |
| KR20240008338A (ko) | 2024-01-18 |
| WO2022241174A1 (en) | 2022-11-17 |
| EP4337648B1 (en) | 2025-12-24 |
| AU2022272725A1 (en) | 2024-01-04 |
| ES3059456T3 (en) | 2026-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013445A (es) | Compuestos heterociclicos sustituidos. | |
| BR112021006229A2 (pt) | composto, composição farmacêutica, e, método para tratamento de um câncer | |
| EA202092253A1 (ru) | Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5 | |
| BR112022020291A2 (pt) | Inibidores de cd38 | |
| BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
| MX2023013351A (es) | Compuestos heterociclicos sustituidos. | |
| BR112022024156A2 (pt) | Compostos heterocílicos antelmínticos | |
| BR112015022575A2 (pt) | composto de fórmula, pró-droga de um composto, kit, métodos para regular uma trajetória, para regular qualquer uma ou mais dentre enzimas, para reduzir metabólitos, para alterar níveis de triptofano, para tratar supressão imunológica, para reduzir ou eliminar um distúrbio imunomediado, para inibir a ativação de enzimas, para tratar uma doença, para inibir uma produção de anticorpo autoimune, para preparar um composto e para diagnosticar e tratar uma doença e composto obtenível por um método | |
| BR112022006507A2 (pt) | Compostos heterocíclicos de arilmetileno como bloqueadores de canais de agitador de potássio kv1.3 | |
| SA520411783B1 (ar) | مشتقات إيميدازول مكثفة بها استبدال بمجموعات هيدروكسي ثلاثية كمثبطات جاما لـ pi3k- | |
| BR0315158A (pt) | Compostos de pirazol para o tratamento de distúrbios neurodegenarativos | |
| BR112015026410A2 (pt) | derivados de dolastatina 10 e auristatinas | |
| BR112021017831A2 (pt) | Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose | |
| EA202090068A1 (ru) | Соединения, влияющие на синтез пигмента и их применение для лечения бактериальных заболеваний | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| SA523451905B1 (ar) | Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات | |
| BR112021019817A2 (pt) | Compostos de pirrol | |
| MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
| CY1109569T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| EA202091804A1 (ru) | Гетероциклил-замещенные оксадиазолопиридиновые производные для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat) | |
| BR112021024300A2 (pt) | Formas de sais cristalinas de um inibidor de quinase | |
| BR112021019099A2 (pt) | Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios | |
| BR112022008223A2 (pt) | Métodos de tratamento e/ou prevenção de eventos cardiovasculares adversos maiores (ecam) com uma combinação de um inibidor do bromodomínio bet e um inibidor da proteína de transporte de glicose dependente de sódio 2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |